Collectively, our data uncover a novel mechanism of trastuzumab resistance driven by circular RNA-encoded peptides, meanwhile provide a proof-of-concept demonstration for a potential strategy to resensitize trastuzumab-resistant HER2-positive breast cancer patients to trastuzumab. This evidence concerns the gene ERBB2 and breast cancer.